Business · 06/11/20261 min read

CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue

Summary

Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose, is ...

Original source language: ANTARA News — Press ReleasesOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Trade Regulation News Global Markets News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News Central Bank Policy News

Related business signals

Business · 11/6/2026

"Permanent Heritage, Harmonious Asia Pacific"

A news report from China Report ASEAN: On November 4, the opening ceremony of the special ...

Read summary →

Business · 11/6/2026

Global solidarity delivers a major boost to Education Can't Wait as the "Hope Starts Here" campaign approaches its US$600 million goal

Governments announce US$405.8 million in new pledges at the Geneva Refurbishment Conference, bringing ECW to 90% of its funding target and opening up new pathways for innovative partnerships to support education for...

Read summary →

Business · 11/5/2026

BayCare Proton Center Treats First Patient on Mevion S250 FITTM with Leo Cancer Care's Marie® Solution

BayCare Health System in Florida becomes the second site to offer upright proton therapy using Mevion's compact system, Leo Cancer Care's upright positioning and imaging technology, and RaySearch's treatment...

Read summary →

Business · 11/5/2026

Menarini group and liver therapeutics, relapsed pre-treatment therapy, reactive, nonresponsive aggressive B cells, non-hyozycin lymphoma target doping tips ((MEN1703, SEL24) JASPIS-01 clinical secondary first data published by 2026 ASH annual scientific journal

The first clinical data of the l-dapoletic tip single therapy: all available standard treatment options are the first results of a JASPIS-01 clinical secondary study evaluating the kinase inhibitor dapoletictip (dapolsertib, MEN1703) amongst class 1 trajectory PIM/FLT3 targeted at patients with degenerative relapsing, nonresponsive, aggressive B cell non-hypocyte lymphoma (B-NHL).

Read summary →

Business · 11/5/2026

ROAD_IF_RCHCAT - "Dataset: updated structure and data"

Recharging points per category of power by NUTS 3 region - experimental statistics

Read summary →

Business · 11/5/2026

ALTA Performance Materials signs an agreement to acquire the Palatal business unit of BASF

The agreement will allow ALTA Performance Materials to expand its manufacturing capabilities in South America and aligns with BASF's strategy of focusing its portfolio on core chemical businesses.

Read summary →